US equities
|
SPCX
$174.26
▲+1.85%
NVDA
$241.75
▲+1.19%
MU
$1,062.72
▼-0.12%
MRVL
$287.07
▲+5.83%
AMD
$637.33
▲+0.88%
SNDK
$1,685.30
▼-1.11%
TSLA
$379.71
▲+0.26%
META
$739.42
▼-0.33%
SPCX
$174.26
▲+1.85%
NVDA
$241.75
▲+1.19%
MU
$1,062.72
▼-0.12%
MRVL
$287.07
▲+5.83%
AMD
$637.33
▲+0.88%
SNDK
$1,685.30
▼-1.11%
TSLA
$379.71
▲+0.26%
META
$739.42
▼-0.33%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
NanoViricides, Inc. Common Stock
(NY:
NNVC
)
1.465
+0.015 (+1.03%)
Delayed Quote
Updated: 9:46 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NanoViricides, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
Today 8:45 EDT
From
NanoViricides
Via
ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Provides Update on Phase II Ebola Trial of NV-387 Oral Gummies
October 05, 2026
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
October 05, 2026
From
NanoViricides
Via
ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Fiscal 2026 Results, Advances NV-387 Phase II Trials
September 29, 2026
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
September 29, 2026
From
NanoViricides
Via
ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Begins Patient Enrollment and Dosing in Phase II NV-387 Ebola Trial
September 28, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
September 28, 2026
From
NanoViricides
Via
ACCESS Newswire
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
September 23, 2026
From
NanoViricides
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Phase II Ebola Trial of NV-387 Oral Gummies Set to Begin Next Week in DRC
September 15, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
September 15, 2026
From
NanoViricides
Via
ACCESS Newswire
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers
From
MarketNewsUpdates.com
Via
GlobeNewswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Registers Phase II Ebola Trial for NV-387 Oral Gummies
September 08, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
September 08, 2026
From
NanoViricides
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Measles Treatment Program Toward Phase II Trial
August 31, 2026
Via
Investor Brand Network
Topics
Intellectual Property
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
August 31, 2026
From
NanoViricides
Via
ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Expects Phase II Ebola Trial of NV-387 Oral Gummies to Begin Soon in DRC
August 18, 2026
Via
Investor Brand Network
Topics
Intellectual Property
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
August 18, 2026
From
NanoViricides
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Regulatory Approval for Phase II Ebola Trial of NV-387 Oral Gummies
August 10, 2026
Via
Investor Brand Network
Topics
Death
Intellectual Property
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
August 10, 2026
From
NanoViricides
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Awaits Regulatory Decision on Ebola Trial for NV-387 Oral Gummies
July 28, 2026
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
July 28, 2026
From
NanoViricides
Via
ACCESS Newswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Approximately $3.8 Million Registered Direct Offering
July 24, 2026
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
July 24, 2026
From
NanoViricides
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Seeks Approval to Launch Phase II Ebola Trial in DRC
July 22, 2026
Via
Investor Brand Network
Topics
Death
Intellectual Property
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
July 22, 2026
From
NanoViricides
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Ethics Approval for Phase II Ebola Trial in DRC
July 13, 2026
Via
Investor Brand Network
Topics
Intellectual Property
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
July 13, 2026
From
NanoViricides
Via
ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Coverage Initiated With Outperform Rating, $6 Price Target
July 08, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
July 08, 2026
From
NanoViricides
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
